



# Nanofacile™ Symphony Kit

## Accelerating RNA therapy discovery & development

**\$50B**  
Global RNA therapies

**30 sec**  
Encapsulation time

**28**  
Parallel formulations

**\$500K USD**  
Dilutive and non dilutive funding

Location: Montréal, QC  
Founded: August 2023

### BUSINESS MODEL

#### Monthly Subscription

- 2025: • \$7.5K/month includes 28 units + systemic delivery recipes  
• Access to the Nanofacile Maestro Formulation Companion (NMFC) as a service
- 2027: Subscription adds AI functions and targeted delivery recipes to the NMFC
- 2028: Joint ventures with customers (IP share, royalties)

#### Revenue Milestone

Paid beta customers in 2025

### TIMELINE

2026

- Launch:**
- RUO commercial product with 50+ customers
  - Formulation companion

2027

- Scale-Up:**
- GLP to GMP transition
  - Clinical scale-up, Version 2.0 and AI features
  - +100 commercial customers
  - >\$2M+ ARR, Seed Round \$5-10M
  - cGMP certification & Two-sided marketplace

### THE PROBLEM

Current LNP formulation solutions are expensive, slow, and expertise-dependent, creating a major bottleneck in RNA therapeutic development.

- **Low-end options:** Cost up to \$40K per formulation, take up to 60 days, with success rates <10%
- **High-end platforms:** Require up to \$300K, extend timelines by 180+ days, demand specialized expertise
- **Success rates:** Rarely exceed 50%, leaving significant technical and financial risk

**Critical unmet need:** Existing solutions lack speed, scalability, and reproducibility, forcing companies to choose between high cost with low success or high capital investment with long development cycles.



### OUR SOLUTION

**Nanofacile™ Symphony Kit** is a turnkey platform that uses Centrifuge-driven consumables run RNA formulations in parallel, paired with proven recipes and a learning software layer that improves with every experiment.

#### Result:

Reduces preclinical development timelines from weeks to days.

#### Key Features:

- **30-second encapsulation** per sample
- **Up to 28 parallel formulations** in a single run
- **Single-use sterile devices** ensuring downstream compatibility
- **Easy integration:** Compatible with standard lab facilities; no new costly equipment
- **Highly reproducible** with high-quality results

### MARKET OPPORTUNITY

**Applications:** Oncology, Infectious Diseases, Rare Genetic Diseases, Inflammatory & Autoimmune Conditions, Respiratory Diseases.

**Momentum:** 340 clinical trials currently recruiting. 17+ mRNA therapies and vaccines already approved.

### COMPETITIVE POSITIONING

**Nanofacile is the only solution explicitly designed for accelerated preclinical R&D with cost-effective subscription pricing.**

Platform	Speed	Cost	Throughput	Sterility
Nanofacile	30 sec	Zero Cap Ex.	28 samples	Yes
Spark PNI (Cytiva)	1 min	\$60K + \$5/sample	Limited	Yes
Sunscreen	3 min	\$300K system	96 well samples	No

### IP STRATEGY

- First provisional patent submitted in 2025
- PCT filings: 2026 (hardware + AI formulation companion)
- Patent-pending platform technology

### TEAM

**Rubén López, Ph.D., CEO & Founder**  
Business Development  
Industry Experience in Nanomedicine

**Angel Valerio, Ph.D., COO (Advisor)**  
Engineering Physics  
Business Operations

**Alejandro Forigua, Ph.D., R&D Chemistry Lead**  
Ph.D. Chemistry

**Prof. Christine DeWolf, Scientific Advisor**  
Ph.D. Chemistry & Biochemistry